PCIB: mRNA er i vinden

[JAXI]

OK jeg sender Mail😃

[JAXI]

mail er nå sendt til ronny - spurte om litt av hvert jeg - stakkars mann
i will keep u guys updated when he replies

[StockDZ]

New Pci related paper published by K.Berg lab 11.Sep.2018 also featured in the journal of control release

https://www.ncbi.nlm.nih.gov/m/pubmed/30217739/

https://www.ous-research.no/home/ous/Homepage%20news/18796

Summary of the findings from Anette Weyergang:

Previous studies have shown the vascular targeted toxin VEGF121/rGel as an effective anticancer modality in combination with the intracellular drug delivery technology photochemical internalization (PCI). It was here hypothesized that VEGF121/rGel-PCI not only exerts its action by destruction of the tumor vasculature, but also stimulate direct cancer parenchymal cell death. The aim of the present study was therefore to elucidate the anticancer mechanisms of VEGF121/rGel-PCI. In contrast to VEGF121/rGel monotherapy, VEGF121/rGel-PCI was found to mediate its effect through VEGFR1 and VEGFR2, and a targeted treatment effect was shown on VEGFR1 expressing cancer cell lines in addition to VEGFR2 expressing endothelial cells. A treatment effect on cancer parenchymal cells was also indicated on H&E stains of CT26-CL25 and 4T1 tumors in addition to inhibited tumor perfusion measured by dynamic contrast enhanced MRI. VEGF121/rGel-PCI showed antitumor efficacy in two aggressive in vivo models (CT26-CL25 and 4T1). An immune-mediated effect was, however, indicated as a prerequisite for complete remission as visualized by the differences in overall treatment response between immunocompetent and athymic mice. In conclusion, the present report indicate VEGF121/rGel –PCI as a treatment modality with multimodal tumor targeted efficacy that should be further developed towards clinicalutilization.

[StockDZ]

Probably this belongs here better!

PCI Biotech Småprat (PCIB)

Hi

Found this project from ETH Zurich (university), I believe this a fimavacc related project, any comments ??

http://www.galenik.ethz.ch/research/particulate-vaccine.html

Quote:
“The latter can be promoted by using the so-called photochemical internalization (PCI), which facilitates antigen release from phagosomes into the cytosol (see Figure)”

Also
“The work on particulate vaccine delivery systems is integrated in long standing collaborations with immunologists”

PCI Biotech Småprat (PCIB)

Further digging in ETH Zurich particulate vaccine project led me to this 2018 Phd position from university of Zurich both universities are collaborating in this.

Link to Phd position and quite a nice job description, I think fimavacc/NAC are getting exciting now:

https://www.academicgates.com/job/detail/7912476b-1ba4-46ba-a36a-6c5d0cc87f9b

Aufgabenbereich / Responsibilities

The appointed PhD student will conduct experimental research on all aspects of cancer immunotherapy utilising a novel method called Photochemical internalisation (PCI), which combines vaccination and photodynamic therapy. The work is done in close collaboration with researchers from the Institute of Pharmaceutical Sciences at ETH Zurich who provide help in formulation of particulate vaccines, e.g. liposomes, and a biotech partner. The PhD student will be developing and testing vaccines in tissue cultures and in mice, and she/he will be using immunological and molecular assessment methods in vitro and in vivo, e.g. FACS, ELISA, immunohistochemistry, immunofluorescence microscopy, PCR and WB. The project is supported by the Swiss National Science foundation, University of Zurich, and a biotech partner .

Here they are talking about developing and testing new vaccines !! Exciting

Also they talk about a biotech partner, who do you think this is? Is it Pci biotech or One of our partners in the collaboration agreements? BioNtech for example ??

[StockDZ]

The biotech partner could well be BioNTech.

If you read below you ll see that our collaboration agreement with BioNtech involves university of Zurich, also in the Phd job description from the university of Zurich, it is mentioned that

“Ideal candidates will also be fluent in German”

https://oslocancercluster.no/2016/09/01/pci-biotech-and-biontech-initiates-preclinical-research-collaboration/

Oslo Cancer Cluster member PCI Biotech is a cancer focused biopharmaceutical company. They have initiated a preclinical agreement with BioNTech AG, which is a fully integrated biotechnology company developing individualized cancer immunotherapies.

The partnership is governed by a preclinical research collaboration agreement. In brief, the preclinical research collaboration will evaluate technology compatibility and synergy based on in vivo studies performed by the University of Zurich. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership. PCI Biotech has already a collaboration agreement with the University of Zurich and the research is funded through the existing agreement.

[StockDZ]

Some intel on Sanofi mRNA ambitions, this was from June this year

Xconomy: With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines

The article also mentions BioNTech exclusive collaboration with Sanofi to develop 5 cancer immune therapies, which was signed 1 year before BioNtech enters into a collaboration agreement with pci biotech, could our technology be the key to BioNtech success in this field?

See below!

[StockDZ]

This is also very interesting from the university of Warsaw

[StockDZ]

This is my second lead on the ETH Zurich and the university of Zurich particulate vaccine delivery system project …

Kindgen_Abstract.pdf

Seems these dry sprayed vaccine particles can be even more efficient than soluble antigens when combined with pci.

[StockDZ]

Since we are discussing fimanac here i thought this post belongs here better

PCI Biotech Småprat (PCIB)

Latest Fimanac publication, study done by university college London and published 18/10/2018

https://pubs.rsc.org/en/content/articlepdf/2018/nr/c8nr04048f

Conclusion :
Endosomal entrapment is a major current issue for the effective delivery of nanomedicines. In this study we have demonstrated that cytosolic delivery of a macromolecule that is normally subject to endosomal entrapment can be achieved via a liposomal nanocarrier that is functionalised so as to codeliver a membrane-localising photosensitiser for a highly efficient PCI effect. This approach thus simultaneously avoids the practical disadvantage of current PCI protocols whereby the photosensitiser and drug are administered separately, while also enabling effective targeting of the photosensitiser towards the endosomal membrane via the peptide component. Unlike other nanocarrier-based approaches, our strategy provides the flexibility to easily vary the loading of the drug to be delivered, while keeping the same level of surface photosensitiser.Moreover, our approach using liposomes as the nanocarrier enables the use of macromolecular drugs as well as small molecule drugs, or even combinations thereof. The modular assembly of the liposomal system also offers scope for the straightforward incorporation of alternative CPPs with inherent tumour-homing properties, as well as other photosensitiser moieties which absorb in the NIR. This should offer a versatile strategy for the targeted and minimally invasive delivery of a range of poorly absorbed therapeutic agents with high potential for clinical translation.The modular assembly of the liposomal system also offers scope for the straightforward incorporation of alternative CPPs with inherent tumour-homing properties, as well as other photosensitiser moieties which absorb in the NIR. This should offer a versatile strategy for the targeted and minimally invasive delivery of a range of poorly absorbed therapeutic agents with high potential for clinical translation.The modular assembly of the liposomal system also offers scope for the straightforward incorporation of alternative CPPs with inherent tumour-homing properties, as well as other photosensitiser moieties which absorb in the NIR. This should offer a versatile strategy for the targeted and minimally invasive delivery of a range of poorly absorbed therapeutic agents with high potential for clinical translation.

[InVivo]

Spennende konferanse iforhold til mRNA!

[idioten]

Kan det være at en av samarbeidspartnerne på nac skal legge frem godsaker hvor de gjør bruk av Amphinex? Ser at både Merck og BioNtec skal være der.

Hvorfor deltagelse på denne konferansen kom først for en uke siden kan vi jo spekulere i.

Men holder meg selvfølgelig til at samarbeidspartner først nå har gitt klarsignal for at de skal presentere noe som har med Amphinex å gjøre.

[StockDZ]

This is conference program, few sessions on delivery but I’m not sure if Pci biotech is presenting something, could be in the poster session

http://mrna-conference.com/fileadmin/user_upload/Final_Schedule_for_mRNA_Health_Conference.pdf

[StockDZ]

I see why @Snoeffelen believes that BioNtech collaboration is the most exciting (probably at least until we know more about top 10 BP)

https://www.siemens.com/customer-magazine/en/home/industry/flexibility-and-modularity-in-pharmaceutical-production/biontech-targeting-cancer.html

Quotes:
Since 2015, in its efforts to optimize production time and costs, BioNTech has been drawing on Siemens’ extensive experience in digitalization to establish a fully automated, paperless, digital manufacturing process. Sahin says, “We aim to be in a position to provide hundreds of thousands of patients with personalized medications within less than five years

Thanks to the global presence of Siemens and the commitment of an international team, all the preconditions for implementation of BioNTech’s planned global production rollout were met. The first market approval of the new vaccine is scheduled for the year 2021.

[solo]

Takker for mye god informasjon. Og den peker dithen at det snart vil foreligge en kjempemelding fra en eller flere av PCIB’s partnere, som vil sende PCIB kursen til himmels.

Bransjen har ventet i flere tiaar paa en leveringsteknologi som virker. Naa er den her og har blitt testet ut i flere aar av vaare partnere. Og resultatene skal snart presenteres. Kommer det gode nyheter fra disse, vil biotec selskaper fra hele verden staa i koe for aa samarbeide med PCIB.

Husk Waldays “Several Strong Response” om fimaNac. Dette maa vaere informasjon han har mottatt fra vaare partnere!

[Columna]

Håper virkelig du er «inne på noe»…

[orionen]

Utrolig hvor lite info man har fra dette prosjektet, utenom en haug av partnere. Håper man kan få noe mer info om dette på Q3. Og at det stilles spørsmål om det. Tydligvis noe veldig attraktivt pcib sitter på her. Grunnet interessen fra både BP og mindre biotek-selskaper.

[Columna]

Helt klart! Tror det blir mange sprs. på tirs…

[Don_suger]

Som de ikke kan svare på…

[Hansine1]

Artikkel; Forskere skal ha funnet dødskode som kan utslette kreft.

Gjennombrudd: Forskere har funnet dødskode som kan utslette kreft

Mange ting her som PCIB sin fimaNAc kan hjelpe til med;

RNA DNA
siRNA
miRNA
aminosyrer

side 22-24

http://pcibiotech.no/wp-content/uploads/2014/01/PCI-Biotech-Company-presentation-June-2018.pdf

Må si fimaNAc og fimaVACC kan bli spennende fremover.

[solo]

Dere har ikke helt forstaatt det enda;-)), men baade fimaVacc og fimaNac naar de blir annerkjent, kommer til aa sende PCIB kursen til 4 siffret. Bankers. Hvilke maaned og aar vi naar denne annerkjennelsen, er vanskelig og si, men tipper det blir neste aar en gang. Og da vil PCIB bli den heteste poteten i verdens farmamarked, med en kursgallopp ikke tidligere sett paa Oslo boers…PCIB vil bli annerkjent som en messias plattform, som alle maa samarbeide med for aa ha noen som helst mulighet til aa vaere konkuransedyktige i utvikling av fremtidens medisiner.